Side-by-side · Research reference

BPC-157vsDSIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed9/53 cited

BHuman-MechanisticDraft8/36 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

01Mechanism of Action

Parameter

BPC-157

DSIP

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014 Sikiric 2018

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Feedback intact?

No known endogenous receptor; mechanism still under investigation

—

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Antibody development

—

02Dosage Protocols

Parameter

BPC-157

DSIP

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

100–200 mcg SQ pre-sleepSchneider 1986

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

Once daily, pre-sleep

Lower / starter dose

200 mcg / day

Conservative starter for new users.

50 mcg pre-sleep

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

Human-mechanistic + early clinicalSchneider 1986

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

8–12 weeks per cycle

Reconstitution

Bacteriostatic water, 1–2 mL

Bacteriostatic water

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

30–60 min pre-sleep

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

Short plasma; CNS effects last hours

04Side Effects & Safety

Parameter

BPC-157

DSIP

Injection site reaction

Mild irritation (anecdotal)

Mild irritation

GI symptoms

None reported in PL-14736 Phase 2

—

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

Avoid

Long-term safety

Unknown beyond Phase 2 trial duration

Limited modern RCT data

Drug interactions

None established

—

Drowsiness

—

Expected effect (intentional)

Vivid dreams

—

Anecdotally reported

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

05Administration Protocol

Parameter

BPC-157

DSIP

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Add 1–2 mL bacteriostatic water to vial.

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

SQ — abdomen. Rotate sites.

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

30–60 min pre-sleep.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

29–31G insulin syringe.

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

DSIP

— no documented stacks